Skip to content
Open access

Terminal V5 Tagging of All Four Newcastle Disease Virus Structural Proteins Is Compatible with Particle Formation in Sf9 Cells

Sep 2026 · International Journal of Molecular Sciences · Vol 27, pp. 8181 · 0 citations · 40 references
Medicine

TL;DR

Particles formed regardless of which structural protein carried the tag, including a variant in which all four proteins were tagged simultaneously, and under the conditions tested, 19-residue terminal insertions were compatible with NDVLP recovery at each of the four positions examined.

Abstract

Newcastle disease virus-like particles (NDVLPs) assemble from the matrix (M), nucleoprotein (NP), fusion (F) and hemagglutinin–neuraminidase (HN) proteins. Terminal epitope tags make these proteins easy to detect but may interfere with assembly, and it is not well-documented how much terminal modification the four proteins tolerate. Eight pFastBac Dual donor plasmids were used to generate recombinant baculoviruses, and twelve NDVLP variants were produced in Sf9 cells and purified by sucrose gradient ultracentrifugation. Particle-like structures were recovered from all twelve preparations. Western blotting confirmed production of the native and V5-tagged proteins and their co-purification in the particle fractions; transmission electron microscopy showed enveloped, roughly spherical particles with measured diameters of 55 to 150 nm (median 90 nm) in every preparation, similar in appearance to native NDV. Particles of a similar size were also present in the beta-glucuronidase control preparation, so the assignment of the particles rests on the protein composition of the fractions rather than on morphology alone. Particles formed regardless of which structural protein carried the tag, including a variant in which all four proteins were tagged simultaneously. Under the conditions tested, 19-residue terminal insertions were compatible with NDVLP recovery at each of the four positions examined.

Read PDF

Similar papers

#protein folding Open access Sep 2026

Functional study of intrinsically disordered region of porcine circovirus type 2 capsid protein for fusing foreign epitope.

The results demonstrate the promising potential of PCV2 VLPs as versatile epitope-display platforms, while establishing the IDR as a suitable fusion site that maintains both structural integrity and biological functionality.

Hong Li, Xiao-Ming Huang, Yu-Xin Zhao et al. · 0 citations
#protein folding Aug 2026

[Mild solubilization, purification, and immunoreactivity characterization of VP1 inclusion body protein of serotype O foot-and-mouth disease virus based on sodium lauroyl sarcosinate].

The LSN-based mild solubilization and chromatographic purification process developed in this study successfully circumvents the destructive effects and complex refolding steps associated with conventional strong denaturants, and the prepared recombinant His-VP1 protein possesses the potential to serve as a high-quality...

Lei Fan, Jianpeng Liang, Jieshan Lin et al. · 0 citations
Open access Sep 2026

Generation and characterization of a PRRSV-2 DIVA marker virus by deletion of a novel epitope in the nucleocapsid protein

The feasibility of developing a PRRSV DIVA vaccine through targeted modification of an N protein epitope is demonstrated, providing a potential strategy to facilitate PRRS control and suggests that combining the recombinant virus with cELISA diagnostic tests allows accurate differentiation between vaccinated and wild-t...

Ji-Wen Sun, Jian Wang, Kun Li et al. · 0 citations
Sep 2026

Revisiting the function of the HSV-1 UL45 protein.

Recombinant viruses containing either glycoprotein B (gB) or glycoprotein K (gK) mutations that confer a syncytial phenotype, and with or without UL45 expression, were generated to revisit the role of 18K in mediating cell fusion and showed that UL45 expression was not required for either gB- or gK-driven syncytial pla...

R. Visalli, M. Visalli · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.